Y Combinator

Yemaachi Biotechnology uses cutting-edge immunogenomics, bioinformatics, and artificial intelligence to accelerate the development of cancer detection and cure strategies for lowering the economic burden of cancer.

NanoNets is machine learning API for developers which requires 1/10th of data and no machine learning expertise to train a model. Upload the data, wait for a few minutes and get a model you can query over their easy to use cloud API. Often companies do not have enough data to train a machine learning model on their own using state of the art algorithms as well as don't have enough data scientists to work on those problems. NanoNets solves both these problems for companies.

Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and nanofluidics.

Dnovobio is a developer of a direct reprogramming technology intended to create any cell, tissue, or organ on demand. Its company's platform converts skin into functional brain cells. The company is currently operating in Stealth mode.

Benchling, Inc. is a developer of a cloud-based informatics platform tailored for life sciences research and development. The platform encompasses a range of integrated applications that enable scientists to design, share, and document experiments efficiently. Key offerings include an electronic lab notebook for experiment documentation, a biological registration system for managing inventory like plasmids and antibodies, and analytical tools for visualizing and collaborating on structured data. Benchling's software supports cutting-edge research techniques such as CRISPR and CAR-T immunotherapy, facilitating advancements in biotherapeutics, biofuels, and biomaterials. The company's solutions are utilized by researchers in biotech and pharmaceutical companies, as well as academic and government labs, streamlining workflows and enhancing collaboration across various research projects. Founded in 2012, Benchling is headquartered in San Francisco, California.

Yemaachi Biotechnology uses cutting-edge immunogenomics, bioinformatics, and artificial intelligence to accelerate the development of cancer detection and cure strategies for lowering the economic burden of cancer.

BluumBio develops cutting-edge bioremediation technologies and services, offering scalable solutions for companies of all sizes. BluumBio makes bacteria and plants eat toxic chemicals that clean up pollution.

Accelerating the discovery of immunotherapies

Known Medicine is looking to take the experimentation of how tumors respond to cancer drugs out of the patient’s body and into the lab. The startup breaks down tumor samples into micro tumors, which they treat separately inside specialized micro-environments with different methods and see what works best.

Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and nanofluidics.

Atom Bioworks specializes in developing a pattern-recognition-enabled sensing and therapeutics platform aimed at enhancing medical applications for the early diagnosis and treatment of infectious diseases and cancer. The company's innovative platform leverages computational biology, quantum chemistry, software, and machine learning to identify diseased surface protein patterns. By creating corresponding pattern-matching constructs, Atom Bioworks provides researchers with advanced nano-pattern recognition capabilities, ultimately facilitating improved diagnostic and therapeutic strategies in the medical field.

Known Medicine is looking to take the experimentation of how tumors respond to cancer drugs out of the patient’s body and into the lab. The startup breaks down tumor samples into micro tumors, which they treat separately inside specialized micro-environments with different methods and see what works best.

Atomwise Inc. is a deep learning AI technology for structure-based small molecule drug discovery. Atomwise performs hundreds of projects per year in partnership with some of the world’s largest pharmaceutical and agrochemical companies, as well as more than 200 universities and hospitals in 40 countries. Its speed and accuracy make it the most advanced technology for small molecule binding affinity prediction. AtomNet, its AI platform built for drug discovery contains more than 16 billion molecules for virtual screening.

Menten AI, Inc. is an early-stage drug discovery company based in San Francisco, California, with an additional location in Toronto, Canada. Founded in 2018, the company focuses on developing protein-based drugs and enzymes using advanced technologies, specifically machine learning and quantum computing. Menten AI addresses the complex challenge of designing proteins, which can adopt numerous shapes, by leveraging quantum computing to represent multiple protein states simultaneously. This innovative approach allows for more efficient identification of optimal protein designs. The company has achieved significant milestones, including creating the world’s first peptide designed on a quantum computer, and is currently working on peptide therapeutics aimed at treating oncology and neurodegeneration, as well as enzymes for various industrial applications.

AI for new drug discovery

Operator is building a low-code platform that makes it easy to build business applications. With Operator, analysts can build software solutions to common problems and bottlenecks without worrying about managing data or setting up integrations.

Advano, operating under NanoStar, Inc., is a New Orleans-based company specializing in silicon nanotechnology. Founded in 2014, Advano develops and produces functionalized silicon nanoparticles and quantum dots for various applications. Notably, its products enhance the energy density of lithium-ion batteries by 30-40%, making them suitable for electric vehicles, consumer electronics, and IoT devices, all without compromising battery life or increasing costs. Additionally, Advano's technology is applied in CO2 carbon capture, super hydrophobic coatings, and printable electronics, serving industries such as telecommunications.

Nplex Biosciences is a biotechnology company based in the United States that specializes in proteomic technology. The company has developed a platform that utilizes DNA nanotechnology to understand, detect, and treat diseases. Nplex offers a range of instruments and automation tools for measuring multiple proteins from blood samples, providing cost-effective solutions for protein data analysis. Its technology integrates seamlessly with industry-standard cytometers, enabling high-throughput analysis and the development of custom protein panels. Nplex aims to enhance existing instruments and workflows while facilitating automation in proteomic research and applications.

Advano, operating under NanoStar, Inc., is a New Orleans-based company specializing in silicon nanotechnology. Founded in 2014, Advano develops and produces functionalized silicon nanoparticles and quantum dots for various applications. Notably, its products enhance the energy density of lithium-ion batteries by 30-40%, making them suitable for electric vehicles, consumer electronics, and IoT devices, all without compromising battery life or increasing costs. Additionally, Advano's technology is applied in CO2 carbon capture, super hydrophobic coatings, and printable electronics, serving industries such as telecommunications.

Nplex Biosciences is a biotechnology company based in the United States that specializes in proteomic technology. The company has developed a platform that utilizes DNA nanotechnology to understand, detect, and treat diseases. Nplex offers a range of instruments and automation tools for measuring multiple proteins from blood samples, providing cost-effective solutions for protein data analysis. Its technology integrates seamlessly with industry-standard cytometers, enabling high-throughput analysis and the development of custom protein panels. Nplex aims to enhance existing instruments and workflows while facilitating automation in proteomic research and applications.

Benchling, Inc. is a developer of a cloud-based informatics platform tailored for life sciences research and development. The platform encompasses a range of integrated applications that enable scientists to design, share, and document experiments efficiently. Key offerings include an electronic lab notebook for experiment documentation, a biological registration system for managing inventory like plasmids and antibodies, and analytical tools for visualizing and collaborating on structured data. Benchling's software supports cutting-edge research techniques such as CRISPR and CAR-T immunotherapy, facilitating advancements in biotherapeutics, biofuels, and biomaterials. The company's solutions are utilized by researchers in biotech and pharmaceutical companies, as well as academic and government labs, streamlining workflows and enhancing collaboration across various research projects. Founded in 2012, Benchling is headquartered in San Francisco, California.

AI for new drug discovery

Autonomous vehicles are poised to deliver transformational benefits to drivers and society, but their sensor systems remain critically vulnerable to common environmental stresses such as stone impact and buildup of bug splatter, dirt, rain, snow, etc. At Alchemy, we aim to improve and preserve human lives by empowering vehicle safety systems to reliably function in all climates and road conditions. We are sustainably and responsibly developing and commercializing nanocoatings to protect these systems from critical damage and loss of vision.

Rain Neuromorphics Inc. specializes in the development of advanced nanotechnology-based chips designed for artificial intelligence applications. The company's flagship product, the Memristive Nanowire Neural Network (MN3), enables AI to process data directly on the chip, facilitating on-device learning. This innovative approach mimics the computational efficiency of the human brain, allowing for valuable insights into biological brain operations. By shifting learning tasks from traditional data center architectures to compact, energy-efficient chips suitable for devices like smartphones, Rain Neuromorphics significantly enhances low-power and cost-effective localized AI processing. Founded in 2017 and based in Gainesville, Florida, the company aims to revolutionize AI technology through its cutting-edge neural network solutions.

Rain Neuromorphics Inc. specializes in the development of advanced nanotechnology-based chips designed for artificial intelligence applications. The company's flagship product, the Memristive Nanowire Neural Network (MN3), enables AI to process data directly on the chip, facilitating on-device learning. This innovative approach mimics the computational efficiency of the human brain, allowing for valuable insights into biological brain operations. By shifting learning tasks from traditional data center architectures to compact, energy-efficient chips suitable for devices like smartphones, Rain Neuromorphics significantly enhances low-power and cost-effective localized AI processing. Founded in 2017 and based in Gainesville, Florida, the company aims to revolutionize AI technology through its cutting-edge neural network solutions.

Rejuvenation Technologies Inc. develops nucleoside-modified telomerase reverse transcriptase messenger ribonucleic acid to extend telomeres for human health extension. It offers cell therapies, which includes tissue engineering, tissue and cell transplants, skin grafts, immunotherapy, and regeneration medicine. The company was incorporated in 2016 and is based in Mountain View, California.

64x Bio is a biotechnology company based in San Francisco, California, founded in 2017 by Alexis Rovner, George Church, Jeffrey Way, and Pamela Silver. The company specializes in designing microorganisms with enhanced properties to facilitate advanced applications in biomanufacturing, bioremediation, and health. By creating cells tailored for specific purposes, 64x Bio aims to enable innovative solutions that were previously unattainable in these fields.

Demonpore is a United States-based company that specializes in the development of biomolecular sensors designed to measure molecules pertinent to human health. The company focuses on creating mechanical nanopores as part of its molecular sensing platform. Headquartered in Oakland, California, Demonpore aims to advance health-related measurements through innovative technology in biomolecular sensing.

Macromoltek does computational drug discovery for pharma companies, focusing on antibodies for therapeutics and diagnostics. This mother-daughter team’s approach aims to make research for everything from flu to cancer treatments an order of magnitude faster. With an accelerated process to discover antibodies, medical researchers can (1) craft targeted treatment plans for previously undruggable targets and (2) overcome patients’ drug resistance, a major challenge when treating diseases caused by bacteria, viruses, and parasites.

Atomwise Inc. is a deep learning AI technology for structure-based small molecule drug discovery. Atomwise performs hundreds of projects per year in partnership with some of the world’s largest pharmaceutical and agrochemical companies, as well as more than 200 universities and hospitals in 40 countries. Its speed and accuracy make it the most advanced technology for small molecule binding affinity prediction. AtomNet, its AI platform built for drug discovery contains more than 16 billion molecules for virtual screening.

Avro Life Science is a Canadian company focused on developing transdermal drug delivery systems, specifically medicated skin patches designed for the pediatric and elderly populations. Utilizing a novel biopolymer as a platform, Avro's technology enables passive delivery of small molecules and drugs directly into the bloodstream, allowing for a slow-release mechanism. This innovative approach aims to enhance medication accessibility while minimizing the impact on the liver, ultimately improving health outcomes and quality of life for its patients.

Advano, operating under NanoStar, Inc., is a New Orleans-based company specializing in silicon nanotechnology. Founded in 2014, Advano develops and produces functionalized silicon nanoparticles and quantum dots for various applications. Notably, its products enhance the energy density of lithium-ion batteries by 30-40%, making them suitable for electric vehicles, consumer electronics, and IoT devices, all without compromising battery life or increasing costs. Additionally, Advano's technology is applied in CO2 carbon capture, super hydrophobic coatings, and printable electronics, serving industries such as telecommunications.

Helix Nanotechnologies uses artificial intelligence to help cure genetic diseases. HelixNano is a Y Combinator and venture backed biotech startup. At HelixNano, we have spent the last two years developing cancer vaccines. Now we are adapting our synthetic biology arsenal to take on COVID-19. We’re moving fast but thinking long-term. We’re already testing COVID-19 vaccine candidates designed to be precise and safe. Our next goal is to create a vaccine that protects everyone not only from this virus, but all future coronaviruses.

Arylla Inc. is a Canadian company specializing in nanotechnology-based invisible ink designed for fraud detection in luxury goods. Founded in 2015 and based in Winnipeg, Arylla's ink assists resellers in verifying the authenticity of high-value items such as leather goods, footwear, and ready-to-wear clothing. The company collaborates with luxury brands, applying its ink during production and facilitating a revenue-sharing model that enables these brands to monetize the resale of their products while combating counterfeit sales. Additionally, Arylla offers a tiered security platform for printing invisible labels that support food authentication and develops scanners for verifying fluorescent signatures.

NanoNets is machine learning API for developers which requires 1/10th of data and no machine learning expertise to train a model. Upload the data, wait for a few minutes and get a model you can query over their easy to use cloud API. Often companies do not have enough data to train a machine learning model on their own using state of the art algorithms as well as don't have enough data scientists to work on those problems. NanoNets solves both these problems for companies.

GTRACK Technologies provides nanoparticle tracers for reservoir characterization. Its nanoparticle tracer solution enables real-time, stage-specific hydraulic fracturing, and oilfield statistics for the optimization of recovery techniques. GTRACK Technologies is a U.S.-based company that was founded in 2015 by Teddy Guenin and Ashwin Amurthur.

At Silver, they are building the world's first miniaturized Raman spectroscope for consumers. Our spectroscope, combined with our proprietary nanoparticle substrates, enables our users to detect many contaminants instantaneously.

Cryopreserving people's healthy young cells for use with future medical technologies.

Atomwise Inc. is a deep learning AI technology for structure-based small molecule drug discovery. Atomwise performs hundreds of projects per year in partnership with some of the world’s largest pharmaceutical and agrochemical companies, as well as more than 200 universities and hospitals in 40 countries. Its speed and accuracy make it the most advanced technology for small molecule binding affinity prediction. AtomNet, its AI platform built for drug discovery contains more than 16 billion molecules for virtual screening.

At 20n, They use algorithms to engineer microbes. Specifically, their algorithms engineer microbes to make chemicals. Like yeast produces alcohol during beer brewing, their engineered microbes will produce chemicals with therapeutic health and industrial biotech applications. The best illustration of this DARPA-backed technology is the bacteria They engineered to produce Paracetamol (also known as acetaminophen, and sold under the brand name Tylenol). Aside from this bacteria, there is no known natural way of producing acetaminophen. They are building data mining technology that will allow us to enable the bioproduction of a whole spectrum of valuable molecules. Below is the map of every chemical that can be made biologically, as discovered by 20n's algorithms.

Autonomous vehicles are poised to deliver transformational benefits to drivers and society, but their sensor systems remain critically vulnerable to common environmental stresses such as stone impact and buildup of bug splatter, dirt, rain, snow, etc. At Alchemy, we aim to improve and preserve human lives by empowering vehicle safety systems to reliably function in all climates and road conditions. We are sustainably and responsibly developing and commercializing nanocoatings to protect these systems from critical damage and loss of vision.

Bikanta Corporation specializes in developing nanodiamond-based technologies for medical imaging applications. Founded in 2013 and headquartered in Newark, California, the company offers optical probes designed for enhanced brightness, signal stability, biocompatibility, and customizability. Bikanta's innovative technology facilitates researchers in addressing complex medical questions and aids healthcare professionals in detecting diseases that are currently difficult to identify. Additionally, the company is involved in designing advanced imaging scanners and microscopes, which aim to improve detection capabilities in medical diagnostics. With a focus on pushing the boundaries of existing optical imaging methods, Bikanta's nanotechnology has the potential to revolutionize the field of nanomedicine, ultimately enhancing surgical control at the cellular level.

Benchling, Inc. is a developer of a cloud-based informatics platform tailored for life sciences research and development. The platform encompasses a range of integrated applications that enable scientists to design, share, and document experiments efficiently. Key offerings include an electronic lab notebook for experiment documentation, a biological registration system for managing inventory like plasmids and antibodies, and analytical tools for visualizing and collaborating on structured data. Benchling's software supports cutting-edge research techniques such as CRISPR and CAR-T immunotherapy, facilitating advancements in biotherapeutics, biofuels, and biomaterials. The company's solutions are utilized by researchers in biotech and pharmaceutical companies, as well as academic and government labs, streamlining workflows and enhancing collaboration across various research projects. Founded in 2012, Benchling is headquartered in San Francisco, California.